These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 1478997)

  • 1. Endocrinological environment with regard to the number of microcysts in patients with polycystic ovary syndrome.
    Yoshino K; Takahashi K; Eda Y; Okada S; Kitao M
    Hum Reprod; 1992 Oct; 7(9):1201-4. PubMed ID: 1478997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transvaginal ultrasound imaging, histopathology and endocrinopathy in patients with polycystic ovarian syndrome.
    Takahashi K; Eda Y; Abu-Musa A; Okada S; Yoshino K; Kitao M
    Hum Reprod; 1994 Jul; 9(7):1231-6. PubMed ID: 7962423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
    van der Westhuizen S; van der Spuy ZM
    Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
    Holte J; Bergh T; Gennarelli G; Wide L
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the influence of ovarian small cysts on endocrine in patients with polycystic ovaries.
    Takahashi K; Uchida A; Yamasaki H; Ozaki T; Yoshino K; Kitao M
    Gynecol Obstet Invest; 1994; 38(2):117-21. PubMed ID: 7959338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
    Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals.
    Pache TD; Hop WC; de Jong FH; Leerentveld RA; van Geldorp H; Van de Kamp TM; Gooren LJ; Fauser BC
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):565-71. PubMed ID: 1424181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal and clinical effects of multifollicular puncture and resection on the ovaries of polycystic ovary syndrome.
    Utsunomiya T; Sumioki H; Taniguchi I
    Horm Res; 1990; 33 Suppl 2():35-9. PubMed ID: 2151330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound.
    Carmina E; Wong L; Chang L; Paulson RJ; Sauer MV; Stanczyk FZ; Lobo RA
    Hum Reprod; 1997 May; 12(5):905-9. PubMed ID: 9194637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of chronic and acyclic elevation of circulating androstenedione or estrone concentrations on ovarian function in the rhesus monkey.
    Billiar RB; Richardson D; Anderson E; Mahajan D; Little B
    Endocrinology; 1985 Jun; 116(6):2209-20. PubMed ID: 3922743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
    Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
    Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which hormone tests for the diagnosis of polycystic ovary syndrome?
    Robinson S; Rodin DA; Deacon A; Wheeler MJ; Clayton RN
    Br J Obstet Gynaecol; 1992 Mar; 99(3):232-8. PubMed ID: 1296589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment.
    Suikkari AM; MacLachlan V; Montalto J; Calderon I; Healy DL; McLachlan RI
    Hum Reprod; 1995 Mar; 10(3):513-9. PubMed ID: 7782424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian response patterns to human menopausal gonadotropin in mixed hyperandrogenemia.
    Hamori M; Török A; Zwirner M; Tinneberg HR
    Acta Endocrinol (Copenh); 1990 Dec; 123(6):598-602. PubMed ID: 2149487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.